Neurocrine Biosciences Beyond Ingrezza: Why the CRENESSITY and VYKAT XR Ramp Points to 37% Upside in 2026
Neurocrine Biosciences (NBIX) beyond INGREZZA: record Q2 revenue, a fast-ramping CRENESSITY launch, and VYKAT XR turn a single-product story into a three-blockbuster growth case with ~37% upside.